Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Leronlimab (codenamed PRO 140) is a humanized monoclonal antibody targeted against the CCR5 receptor found on T lymphocytes of the human immune system. It is being investigated as a potential therapy in the treatment of triple negative breast cancer and HIV infection.
The analysis highlights Development, Mechanism of action and Overview as prominent areas in the source structure around Leronlimab.
Source areas are shown by the number of related topics found in each part of the analysis. Use smaller areas too: they can reveal specialized angles and content gaps.
Smaller areas are not necessarily less important. They contain fewer connections in this analysis and can be useful for finding specialized angles or coverage gaps.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Explore different angles and find fresh ideas to shape your next piece of content.
Search suggestions related to this topic. Open a question to research it further; suggestions are not verified answers.
Browse the complete topic structure, not only the most central items. Less prominent entities and concepts can reveal missing angles, specialized context and useful research gaps. Each item opens a new analysis centered on that subject.
You can skip this section if you’re here for content ideas and keyword inspiration.
The extracted context around Leronlimab shows recurring relationship patterns in the source. For example, Leronlimab → ART, ASM Microbe, August, BLA, CytoDyn, Cytodyn Inc, FDA, HAART, HIV, HIV RNA, HIV-1 RNA, HIV-infected, In December, In February, In March, In May, January, Participants, PRO, PRO140 Another extracted example is Leronlimab → CD10, CD12, COVID-19, CytoDyn, Inc. Use these groups to spot repeated connection types before inspecting the individual relationships.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
pro 140 cytodyn patients ccr5 hiv antibody trial treatment breast 2019 cancer drug covid-19 viral monoclonal also humanized fda mtnbc
TTTA extracted 39 structured relationships around Leronlimab. Examples in this analysis include Leronlimab → ATC code → none and Leronlimab → CAS Number → 674782-26-4 Y. The table shows each extracted connection, where it came from and its confidence.
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Leronlimab | ATC code | none | 1.00 | infobox |
| Leronlimab | CAS Number | 674782-26-4 Y | 1.00 | infobox |
| Leronlimab | ChEMBL | ChEMBL2109343 | 1.00 | infobox |
| Leronlimab | ChemSpider | none | 1.00 | infobox |
| Leronlimab | DrugBank | DB05941 Y | 1.00 | infobox |
| Leronlimab | KEGG | D11399 | 1.00 | infobox |
| Leronlimab | NIAID ChemDB | 088103 | 1.00 | infobox |
| Leronlimab | Other names | PRO 140 | 1.00 | infobox |
| Leronlimab | Source | Humanized | 1.00 | infobox |
| Leronlimab | Target | CCR5 | 1.00 | infobox |
| Leronlimab | Type | Whole antibody | 1.00 | infobox |
| Leronlimab | UNII | Y1J4NP8FF0 | 1.00 | infobox |
The concept neighborhoods around Leronlimab bring nearby vocabulary together. In this analysis, examples include Cytodyn, Also and Patients. Use the clusters to find adjacent concepts and terminology that may deserve separate research.
For Leronlimab, one of the stronger structural bridges in this analysis connects Leronlimab with Development. Bridges highlight paths between different parts of the map and can reveal research angles that are easy to miss in a flat list.
TTTA analyzes the structure around Leronlimab to surface related topics, entities, relationships, concept neighborhoods and bridge connections. Use the map to explore areas such as Development, Mechanism of action & Overview, including less central topics that may reveal useful research gaps. Automatically extracted connections are research leads rather than rewritten encyclopedia content.
Source: Wikipedia — Leronlimab · EN edition · Analysis: TopicsToTalkAbout